During a live event, Omid Hamid, MD, discussed the logistics and multidisciplinary process of using tumor-infiltrating ...

SHANGHAI, April 28, 2025 /PRNewswire/ -- Shanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics), a clinical-stage biotech specializing in developing innovative IL-2-independent ...

Six presentations highlight innovations designed to shorten TIL manufacturing, new nonclinical data on LYL119, new technologies and clinical trials in progress SOUTH SAN FRANCISCO, Calif., Oct. 31, ...

Adoptive cell transfer, in which a patient’s own immune defenses are boosted or rewired to kill cancer cells, is one of the most effective forms of personalized cancer care to ever reach patients.

Xcell Biosciences Australia, an affiliate of Xcell Biosciences, and Royal Perth Hospital agreed to collaborate on developing an automated, clinical-scale manufacturing workflow for therapies based on ...